We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


How Are Label-Free Technologies Used in Early Drug Discovery?

How Are Label-Free Technologies Used in Early Drug Discovery? content piece image

Most small molecule drugs and biologics, including monoclonal antibodies, interact with a therapeutic target to alter its function. Traditional analytical techniques such as fluorescence-based assays involve tagging analytes or secondary reagents with a fluorescent moiety. Labeling is typically not site-specific and can lead to structural alterations that may affect its activity. Data quality issues can also arise due to interference from fluorescent labels.

Modern analytical techniques designed for real-time analysis and high-throughput capabilities significantly reduce the time taken to discover promising therapeutics with the best chances for success downstream.

Download this eBook to learn about label-free solutions that:

  • Reduce the time it takes to identify, select and optimize drug candidates
  • Allow for high-throughput target specificity analysis
  • Facilitate the selection of clones less likely to fail downstream